(a) As used in this chapter, the following terms shall be defined as provided in this section:(a) “Department” means the State Department of Health.(b) “Drug developer” means a pharmaceutical company, biotechnology company, or contract development and manufacturing organization engaged in drug development and manufacturing.(c) “FDA” means the United States Food and Drug Administration.(d) “Hospital” has the meaning as defined in Section 41-9-3.(e) “Ibogaine” means ibogaine and ibogaine-based therapeutics, including ibogaine analogs.(f) “Lead consortium” means the consortium that is first established by the government of another state.
(a) “Department” means the State Department of Health.
(b) “Drug developer” means a pharmaceutical company, biotechnology company, or contract development and manufacturing organization engaged in drug development and manufacturing.
(c) “FDA” means the United States Food and Drug Administration.
(d) “Hospital” has the meaning as defined in Section 41-9-3.
(e) “Ibogaine” means ibogaine and ibogaine-based therapeutics, including ibogaine analogs.
(f) “Lead consortium” means the consortium that is first established by the government of another state.